An experimental cancer drug discovered at Oxford University is the focus of a new UK biotech company to be listed in London this week led by two veterans of Bristol-Myers Squibb, the large US pharmaceuticals group.
Failed Polish oil and gas investor 3Legs will relaunch on the junior market as a cancer drug company backed by multi-millionaire investor Jim Mellon.
Tumors contain the seeds of their own destruction. We just need to work out how to activate them.
Blueprint Medicines said today it is launching a $1 billion-plus collaboration with Roche to discover, develop, and commercialize up to five small-molecule therapeutics targeting kinases deemed important in cancer immunotherapy.
The immune system can be a powerful weapon against cancer — but researchers are still grappling with how to control it.
Just weeks after AstraZeneca ($AZN) reported a success for a combination study of durvalumab and tremelimumab, the pharma giant has been forced to concede that the CTLA-4 drug tremelimumab flunked a solo challenge for mesothelioma.